Table 4.

Bivariate analysis taking the resistance to treatment, evaluated by the PANSS scale, as the dependent variable.

		Resistance to Treatment (PANSS)
		No	Yes	p-Value
		Frequency (%)	Frequency (%)
Gender	Male	11(16.9%)	16(45.7%)	0.002
	Female	54(83.1%)	19(54.3%)
Level of education	Primary	29(53.7%)	13(46.4%)	0.036
	Secondary	23(42.6%)	9(32.1%)
	University	2(3.7%)	6(21.4%)
Consumption of psychoactive substances	No	65(100.0%)	27(87.1%)	0.003
	Yes	0(0.0%)	4(12.9%)
Family history of schizophrenic episodes	No	47(73.4%)	15(51.7%)	0.040
	Yes	17(26.6%)	14(48.3%)
Psychotherapy	No	53(88.3%)	20(71.4%)	0.050
	Yes	7(11.7%)	8(28.6%)
Treatment by benzodiazepines	No	41(63.1%)	29(82.9%)	0.040
	Yes	24(36.9%)	6(17.1%)
Treatment by anticholinergic drugs	No	23 (35.4%)	3 (8.6%)	0.004
	Yes	42 (64.6%)	32 (91.4%)
COMT	VV	23 (35.4%)	11 (31.4%)	0.822
	VM	27 (41.5%)	14 (40.0%)
	MM	15 (23.1%)	10 (28.6%)
COMT (male)	VV	7 (63.6%)	2 (12.5%)	0.023
	VM	3 (27.3%)	9 (56.3%)
	MM	1 (9.1%)	5 (31.3%)
COMT (female)	VV	16 (29.6%)	9 (47.4%)	0.273
	VM	24 (44.4%)	5 (26.3%)
	MM	14 (25.9%)	5 (26.3%)
DRD2	CC	10 (16.1%)	6 (20.0%)	0.897
	CT	32 (51.6%)	15 (50.0%)
	TT	20 (32.3%)	9 (30.0%)
MTHFR	CC	28 (43.1%)	14 (40.0%)	0.520
	CT	25 (38.5%)	17 (48.6%)
	TT	12 (18.5%)	4 (11.4%)
OPRM1	AA	52 (80.0%)	25 (71.4%)	0.331
	AG	13 (20.0%)	10 (28.6%)
	GG	0 (0.0%)	0 (0.0%)
		Mean ± SD	Mean ± SD
Time since the beginning of treatment (years)		2.71 ± 1.92	1.85 ± 1.69	0.080
Chlorpromazine equivalent dose (mg)		1006.28 ± 1232.53	1590.71 ± 1202.11	0.025
Adherence to treatment score (over 8)		6.10 ± 1.37	5.31 ± 1.61	0.010

PANSS: positive and negative syndrome scale; SD: Standard deviation; numbers in bold indicate significant associations between variables.